Bannerbild German Brest Group

GBG Research at ASCO 2022

12.05.2022

GBG Research at ASCO 2022

We are happy to present our research at the ASCO Annual meeting June 2022.

GeparNuevo

Poster #354 6. Juni 2022, 15:00 MESZ
Poster Session: Breast Cancer—Local/Regional/Adjuvant
Presenter: Carsten Denkert
Biomarkers for response to immunotherapy in triple-negative breast cancer: Differences between survival and pCR biomarkers.
Denkert C, Schneeweiss A, Rey J, et al.

GeparNuevo

Poster #352 6. Juni 2022, 15:00 MESZ
Poster Session: Breast Cancer—Local/Regional/Adjuvant
Presenter: Thomas Karn
Low TMB as predictor for additional benefit from neoadjuvant immune checkpoint inhibition in triple-negative breast cancer.
Karn T, Denkert C, Rey J, et al.

Education Session

Integrating Immunotherapy in the Treatment Landscape of Patients With Triple-
Negative Breast Cancer
Presentation: Immunotherapy for Patients With Early-Stage Triple-Negative Breast Cancer: Is the Presence of Tumor Cells Required?
Speaker: Sibylle Loibl, MD, PhD, Time: June 7th 08:00-08:15 am CDT, Location: E450

PALLAS (External)

Poster discussion # 290 6. Juni 2022, 20:15 MESZ
Poster Discussion Session: Breast Cancer—Local/Regional/Adjuvant
Presenter: Georg Pfeiler
Impact of Body Mass Index on treatment and outcomes in early hormone receptor-positive breast cancer patients receiving endocrine therapy with or without palbociclib in the PALLAS trial.
Pfeiler G, et al.


News

GBG Forschungs GmbH
Dornhofstr. 10 | 63263 Neu-Isenburg | Fax +49 6102 7480-440

+49 6102 7480-0 | nfGBGd